SUMMARY Olsalazine (2 g/day) and sulphasalazine (3 g/day) were compared in a double blind three centre trial in 37 patients presenting with first attack of distal colitis. Sigmoidoscopic appearances, rectal biopsies, and symptom and stool diary records were used to assess benefit and adverse effects. Both groups showed a similar decrease in stool frequency (p<0001). The proportion of unformed stools was also decreased, but to a lesser extent (p<005) in those taking olsalazine (78% v 55%; p<O-OOl) compared with those taking sulphasalazine (72% v 28%; p<0001). There was a diminution in the proportion of stools containing blood in both groups (olsalazine: 61% v 22%; p<0001/sulphasalazine: 67% v 37%; p<0O001). Sigmoidoscopic and histological appearances and clinical activity improved significantly and to a similar extent in both groups. Intolerance was encountered in two patients on olsalazine and four on sulphasalazine; intolerance to sulphasalazine being even higher (five of seven patients) in a preliminary study using a dose of sulphasalazine releasing the same amount of 5-aminosalicylic acid as 2 g olsalazine. Olsalazine was at least as effective as sulphasalazine in the treatment of new patients with distal colitis, and in a dose releasing an equivalent amount of 5-aminosalicylic acid was better tolerated.
colitis`' and as effective as sulphasalazine in maintaining remission. Its efficacy as primary treatment, however, has not been established.
In a randomised double blind, double dummy, multicentre clinical trial, we have compared the short term efficacy and tolerance of olsalazine and sulphasalazine in new patients presenting with colitis.
Methods

PATI ENTS
All patients studied were outpatient referrals with their first attack of mild or moderately severe ulcerative colitis,' confirmed by sigmoidoscopic and histological evidence, and negative stool culture for pathogens. Patients were excluded if they had severe colitis or were considered sufficiently ill to require corticosteroids or had hepatic or renal dysfunction. The study was carried out in three centres, but 675 Rao, Dundas, Holdsworth, Cann, Palmer, and Corbett 20 17
Male:female 9:11 8:9 Mean age: years (range) 46 In a preliminary study, we carried out a double blind, double dummy comparison of 2 g olsalazine with 4 g sulphasalazine (enteric coated), administered daily in four equally divided doses. All doses for the first three days contained placebo only, and the full daily dose was attained by gradual increase over a further four days. Eleven patients were entered in this study which was terminated as a high proportion of patients had experienced intolerable adverse effects. After breaking the code it was apparent that all four patients who had received olsalazine had tolerated the drug and improved clinically. In contrast, only two of the seven patients who received sulphasalazine tolerated the drug and improved clinically, the other five having to stop the drug because of intolerable adverse effects. These were nausea and dyspepsia in three patients, headache, dizziness, and arthralgia in one patient, and a rash in one other patient. All patients except the one who developed a rash, experienced adverse symptoms only after receiving the full dose of sulphasalazine, implying that the greater number of withdrawals was caused by dose related intolerance of sulphasalazine. The study was therefore redesigned using the same dose of olsalazine (2 g/day) but a lower dose of enteric coated sulphasalazine (3 g/day). The drugs were, as before, provided in sealed blister packs and were administered four times a day, full dosage being attained gradually over seven days. ETHICAL 
CONSIDERATIONS
The protocol for the study was approved by the Ethical Committee of the Sheffield Health Authority in October, 1984 , and all patients gave a written informed consent.
STATISTICAL ANALYSIS
The significance of the differences in the stool There was a similar improvement (p<0-001) in the mean daily stool frequency in both groups of patients (Table 2 ). An improvement (p<0.001) in the proportion of unformed stools was seen in both groups of patients, but patients in the olsalazine group showed a smaller reduction (p<0-05) than patients in the sulphasalazine group (Table 2) . There was a reduction (p<0001) in the proportion of bloody stools in both groups of patients (Table 3 ).
SIGMOIDOSCOPIC AND HISTOLOGICAL
APPEARANCES
A similar proportion of both groups of patients showed an improvement in sigmoidoscopic (p<0.01) and histological (p<0.01) appearances (Table 2 ).
CLINICAL IMPROVEMENT
There was an improvement in the clinical severity of disease (p<0-001) and overall response (p<0-01) in patients taking olsalazine and sulphasalazine. There was no difference in the clinical response between the two groups (Tables 2 and 3 ).
Discussion
Our study was unique in that none of the patients had received any other therapy for ulcerative colitis before entering the study. Previous trials have compared olsalazine with placebo in patients who were either withdrawn from sulphasalazine'" or were intolerant of this drug.'2'1 Similarly, a large study which compared the relapse prevention properties of olsalazine and sulphasalazine was also conducted in patients whose sulphasalazine was withdrawn."1
We have clearly shown that on the basis of clinical response, sigmoidoscopic appearance, and histological changes that both drugs were effective in inducing a remission within one month in a high proportion of patients with mild or moderately active distal ulcerative colitis. None of the patients who tolerated the drug showed a deterioration in their disease activity. The histological improvement was not as striking as the improvement in sigmoidoscopic appearances or clinical response, and is consistent with previous observations'" that there is a poor correlation between the three methods of assessment and that microscopic evidence of active disease may be seen in the absence of sigmoidoscopic or clinical evidence of activity. Hence, although histological assessment is a more accurate measurement of disease activity, therapeutic benefit assessed by histological improvement lags behind improvement in symptoms and sigmoidoscopic appearance.
Although there was a significant reduction in the proportion of stools which were unformed in both the groups, patients in the olsalazine group voided a significantly higher proportion of unformed stools compared with patients in the sulphasalazine group after but not before treatment. This may be explained by previous physiological studies which showed that olsalazine increases ileostomy output2" and reduces intestinal transit time," both of which could affect stool consistency whereas sulphasalazine does not cause any such effects.""'2 In spite of this effect on stool consistency, there was a significant and comparable reduction in stool frequency. When assessed for clinical and overall improvement, a relatively higher proportion of patients taking olsalazine appeared to improve compared with sulphasalazine (Table 2 ), but this difference was not significant.
In our preliminary study we compared the two drugs using doses which released approximately equal amounts of 5-aminosalicylic acid in the colon.
This study was terminated as many patients in the sulphasalazine group experienced intolerable adverse effects after receiving a daily dose of 4 g enteric coated sulphasalazine. A dose of 4-6 g sulphasalazine would have been required to produce equivalence in terms of 5-aminosalicylic acid release, to 2 g olsalazine. Moreover, even when prescribed a lower dose of sulphasalazine (3 g/day), a lower proportion of patients tolerated this drug. Thus, olsalazine was certainly better tolerated than sulphasalazine when given in comparable dosage, although it must be pointed out that our study was conducted in patients with distal colitis and the tolerance of olsalazine in this group may be different to that of patients with total colitis.'2 In relapse prevention, which is the chief role of these drugs, it is established that 4 g sulphasalazine daily is more effective but tolerated by fewer patients than smaller doses."' Acceptable tolerance by most patients in our study of 2 g olsalazine, which contains approximately as much 5-aminosalicylic acid as 4 g sulphasalazine, suggests that olsalazine could be the preferable drug. 
